{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:24:43Z","timestamp":1683087883388},"reference-count":29,"publisher":"SLACK, Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gerontol Nurs"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>\n            The intent of the current article is to highlight via a case vignette challenges faced when managing pain across care transitions in an older adult with multiple comorbidities, including, but not limited to, opioid use disorder (OUD). This case will highlight the role of different medications for OUD, namely buprenorphine\/naloxone, methadone, and naltrexone. Furthermore, the case illustrates medication-related considerations in addition to action steps that are needed when working with older adults. [\n            <jats:italic>Journal of Gerontological Nursing, 48<\/jats:italic>\n            (7), 4\u20139.]\n          <\/jats:p>","DOI":"10.3928\/00989134-20220607-01","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:26:36Z","timestamp":1656595596000},"page":"4-9","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Use Disorder and Older Adults: Navigating Treatment Options"],"prefix":"10.3928","volume":"48","author":[{"given":"Nicole J.","family":"Brandt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216306pm1127oa"},{"key":"e_1_3_2_3_1","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. (2016). CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016. https:\/\/www.cdc.gov\/mmwr\/volumes\/65\/rr\/rr6501e1.htm","journal-title":"CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000457"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2021.07.001"},{"key":"e_1_3_2_6_1","author":"Federal Register","year":"2021","unstructured":"Federal Register. (2021).Practice guidelines for the administration of buprenorphine for treating opioid use disorder. https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder","journal-title":"Practice guidelines for the administration of buprenorphine for treating opioid use disorder"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.02.002"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15080"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2018.12.026"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2007.9.2\/hkleber"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/hsw\/27.3.193"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-020-00231-x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2011.01.007"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.12.019"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3928\/00989134-20160314-04"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2019.0128"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006605.pub2"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/wentk\/9780190916039.001.0001"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1997.tb00406.x"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8062"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615371624.as50"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.01.010"},{"key":"e_1_3_2_24_1","author":"Substance Abuse and Mental Health Services Administration","year":"2020","unstructured":"Substance Abuse and Mental Health Services Administration. (2020). Treating substance use disorder in older adults: Treatment improvement protocol (TIP) 26. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP20-02-01-011%20PDF%20508c.pdf","journal-title":"Treating substance use disorder in older adults: Treatment improvement protocol (TIP) 26"},{"key":"e_1_3_2_25_1","author":"Substance Abuse and Mental Health Services Administration","year":"2021","unstructured":"Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder: Treatment improvement protocol (TIP) 63. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf","journal-title":"Medications for opioid use disorder: Treatment improvement protocol (TIP) 63"},{"key":"e_1_3_2_26_1","author":"Substance Abuse and Mental Health Services Administration","year":"2022","unstructured":"Substance Abuse and Mental Health Services Administration. (2022). MAT medications, counseling, and related conditions. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions","journal-title":"MAT medications, counseling, and related conditions"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab116"},{"key":"e_1_3_2_28_1","unstructured":"U.S. Food and Drug Administration. (2020 September 23). FDA requiring labeling changes for benzodiazepines: Boxed warning to be updated to include abuse addiction and other serious risks [Press release]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requiring-labeling-changes-benzodiazepines"},{"key":"e_1_3_2_29_1","author":"U.S. Food and Drug Administration","year":"2022","unstructured":"U.S. Food and Drug Administration. (2022). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. https:\/\/www.fda.gov\/media\/155352\/download","journal-title":"FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0898264310386224"}],"container-title":["Journal of Gerontological Nursing"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T02:49:37Z","timestamp":1683082177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/00989134-20220607-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.3928\/00989134-20220607-01"],"URL":"https:\/\/doi.org\/10.3928\/00989134-20220607-01","relation":{},"ISSN":["0098-9134","1938-243X"],"issn-type":[{"value":"0098-9134","type":"print"},{"value":"1938-243X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}